艾伯维公司 ABBV 深 沪
等待开盘 12-05 09:30:00 美东时间
228.71
-1.530
-0.66%
华盛通- 最 高230.94
- 今 开230.11
- 成交量 373.31万股
- 最 低 227.59
- 昨 收 230.24
- 总市值 4041.31亿
- 52周最高 243.17
- 市盈率 静 95.68
- 换手率 0.00%
- 52周最低 159.47
- 委 比 90.48%
- 总股本 17.67亿
- 历史最高 243.17
- 量 比 0.79
- 振 幅 1.46%
- 历史最低 -16.88
- 每 手 1
- 风险率 20.54%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany
SAN DIEGO, Dec. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), announced today that a German court has granted its request for a preliminary injunction orderi...
今天 02:26
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
Denali Therapeutics and Royalty Pharma have entered a $275 million synthetic royalty agreement for tividenofusp alfa, Denali’s enzyme replacement therapy for Hunter syndrome. The FDA is reviewing its BLA for accelerated approval, with a PDUFA date of April 5, 2026. Royalty Pharma will pay $200 million upfront and $75 million upon EMA approval by 2029, receiving a 9.25% royalty on global sales.
12-04 12:00
Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%
Amneal Pharmaceuticals received FDA approval for its 0.05% cyclosporine ophthalmic emulsion, a preservative-free, sterile treatment for dry eye disease, expected to launch Q1 2026. As the generic equivalent of Allergan's RESTASIS, the product highlights Amneal's expertise in complex ophthalmic formulations. With U.S. sales of $2.0 billion in the past year, the drug aims to increase tear production in patients with inflamed eyes. Amneal's approval...
12-01 21:01
AbbVie Scores Canadian Reimbursement Recommendations For Blockbuster Ulcerative Colitis Drug Skyrizi
AbbVie secures Canadian support for Skyrizi in ulcerative colitis with new reimbursement recommendations and a completed pCPA agreement.
11-28 23:50
CMS unveils price reductions for 15 drugs for 2027
Individuals covered under Medicare can expect significant savings on the 15 drugs that were selected earlier this year for drug price negotiations under the Inflation Reduction Act starting in 2027. W...
11-27 01:14
Riding the gravy train: Dividend stocks carving out 20%+ returns
The 2025 trading year has been largely positive for stocks, despite a November pullback that saw increased selling pressures. Major market averages remain firmly in the green for the year, with the Do...
11-27 00:03
Healthcare ETFs Trounce Tech, Grab Billions As Big Money Flees Bubble Fears
Healthcare ETFs are raking in fresh inflows while tech bleeds, reflecting a defensive shift as investors grow wary of frothy valuations.
11-26 22:25
Royalty Pharma to Present at Upcoming Investor Conferences
Royalty Pharma plc (Nasdaq: RPRX) will participate in two investor conferences in December: Citi’s 2025 Global Healthcare Conference on December 2 at 3:15 p.m. ET and Evercore’s 8th Annual Healthcare Conference on December 3 at 3:50 p.m. ET. A live webcast will be available on Royalty Pharma’s “Events” page, with an archive for 30 days. Founded in 1996, Royalty Pharma is the largest purchaser of biopharmaceutical royalties and a key innovator in ...
11-26 13:15
REGENXBIO to Participate in Upcoming Investor Conference
ROCKVILLE, Md., Nov. 25, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conference: Piper Sandler 37th Annual Healthcare Con...
11-25 20:05
AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference
NORTH CHICAGO, Ill., Nov. 24, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025. Management will...
11-24 21:00
